TERN - Terns Pharmaceuticals, Inc.
About Terns Pharmaceuticals, Inc. (https://www.ternspharma.com)
Terns Pharmaceuticals, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to advancing novel small-molecule treatments. Its primary focus lies in developing both standalone agents and combination therapies to address non-alcoholic steatohepatitis (NASH) and obesity. The company's pipeline includes several key drug candidates: TERN-101, a farnesoid X receptor agonist distinguished by its liver-specific distribution and non-bile acid properties, is presently undergoing Phase IIa clinical trials for NASH. TERN-201, a vascular adhesion protein-1 inhibitor, is in Phase Ib clinical studies, also targeting NASH. Terns is also progressing TERN-501, a thyroid hormone receptor beta agonist engineered for improved liver targeting and metabolic resilience, through Phase I clinical trials for NASH. Furthermore, the company is advancing TERN-601, an oral small-molecule Glucagon-Like Peptide-1 receptor agonist program, intended for the management of NASH and various metabolic conditions, including obesity. Established in 2016, Terns Pharmaceuticals maintains its corporate headquarters in Foster City, California.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Amy L. Burroughs | Chief Executive Officer & Director | 1971 | $1,173,388 USD |
| Emil T. Kuriakose | Chief Medical Officer | 1981 | $819,800 USD |
| Andrew W. Gengos | Chief Financial Officer & Head of Corporate Development | 1964 | $700,845 USD |
| Melita Sun Jung | Chief Business Officer | 1977 | $508,886 USD |
| Caryn Gordon McDowell | Chief Legal Officer | 1970 | – |
| Debra Sieminski | Senior Vice President of Medical Affairs | – | – |
| James Kanter | Senior Vice President of CMC | – | – |
| Jeffrey R. Jasper | SVP & Senior Distinguished Research Fellow | – | – |
| Robin Andrulevich | Chief People Officer | 1966 | – |
| Scott Harris | Chief Development & Operations Officer | – | – |
| Theresa Clouser | Vice President of Marketing | – | – |
| Yasameen Qazen | Senior Vice President of Regulatory Affairs & Quality Assurance | – | – |